Dr. Jonathan Freeman
Dr. Freeman currently serves as the Chief Operating Officer of Anthos Therapeutics Inc., a clinical-stage biopharmaceutical company developing therapies for cardiovascular patients. Anthos Therapeutics Inc. was launched by Novartis and Blackstone Life Sciences, a private investment firm, where Dr. Freeman has also served as a Senior Advisor since July 2018. Prior to Anthos, Dr. Freeman was the Chief Business Officer at Vedanta Biosciences and held the role of Senior Vice President of Strategy and Portfolio Management at Merck KGaA. During his tenure, he was responsible for the portfolio and strategic shift that repositioned Merck as a major player in the immuno-oncology space. Dr. Freeman received a Ph.D. in Molecular Pharmacology and Drug Metabolism from the Imperial Cancer Research Fund (now CRUK), an M.A. and First Class Honours in Biochemistry from Cambridge University and a MBA with a finance major from Webster, St. Louis.